Fan Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fan Xiao has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Wei Tao
Department of Pharmacology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
5 shared publications - Dayong Yang
Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, China
3 shared publications Jianhua Zou
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, School of Pharmacy, Hangzhou Normal University
3 shared publicationsJinyue Fan
Department of Neurosurgery Zhujiang Hospital Southern Medical University Guangzhou P. R. China
3 shared publicationsMeng Li
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, School of Pharmacy, Hangzhou Normal University
3 shared publicationsZiwei Liu
Key Lab of Ophthalmology Eye Center of The Second Affiliated Hospital, & Liangzhu Laboratory, & Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (61) , e74994
Cornea‐Penetrating Nanodrug Co‐Delivering VEGF‐Silencing siRNA and Lutein for Treating Age‐Related Macular Degeneration
Age‐related macular degeneration (AMD) is the leading cause of irreversible blindness among the elderly, driven by oxidative stress, chronic inflammation, and pathological choroidal neovascularization (CNV). Although intravitreal anti‐vascular endothelial growth factor (VEGF) therapies remain the current clinical standard, their invasive nature and requirement for long‐term repeated injections present substantial risks and patient burden, underscoring an urgent need for noninvasive therapeutic alternatives. Here, we develop a noninvasive, cornea‐penetrating nanodrug based on chitosan‐modified lipid‐polymer hybrid nanoparticles (LPNPs) for co‐delivery of lutein and VEGF‐silencing siRNA (Chi@Lu/si NPs) to treat AMD. The structurally stabilized nanoparticles overcome the intrinsic instability of siRNA and the poor solubility of lutein, while the chitosan coating confers strong mucoadhesion and transient modulation of epithelial tight junctions, enabling a 3.3‐fold enhancement in trans‐epithelial transport across the ocular surface. Once delivered to the posterior segment, lutein effectively scavenges excessive reactive oxygen species and suppresses inflammatory cascades, whereas siRNA‐VEGF achieves precise VEGF gene silencing, collectively interrupting the pathological cycle driving CNV progression. In a laser‐induced CNV mouse model, topical administration of Chi@Lu/si NPs twice daily exerted potent inhibitory effects on neovascularization, with therapeutic efficacy comparable to that of intravitreal bevacizumab, reducing CNV lesion thickness to 58.9% of pre‐treatment levels while maintaining excellent ocular biocompatibility.
- 15 September 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (61) , e74994
Open AccessCornea‐Penetrating Nanodrug Co‐Delivering VEGF‐Silencing siRNA and Lutein for Treating Age‐Related Macular Degeneration
Age‐related macular degeneration (AMD) is the leading cause of irreversible blindness among the elderly, driven by oxidative stress, chronic inflammation, and pathological choroidal neovascularization (CNV). Although intravitreal anti‐vascular endothelial growth factor (VEGF) therapies remain the current clinical standard, their invasive nature and requirement for long‐term repeated injections present substantial risks and patient burden, underscoring an urgent need for noninvasive therapeutic alternatives. Here, we develop a noninvasive, cornea‐penetrating nanodrug based on chitosan‐modified lipid‐polymer hybrid nanoparticles (LPNPs) for co‐delivery of lutein and VEGF‐silencing siRNA (Chi@Lu/si NPs) to treat AMD. The structurally stabilized nanoparticles overcome the intrinsic instability of siRNA and the poor solubility of lutein, while the chitosan coating confers strong mucoadhesion and transient modulation of epithelial tight junctions, enabling a 3.3‐fold enhancement in trans‐epithelial transport across the ocular surface. Once delivered to the posterior segment, lutein effectively scavenges excessive reactive oxygen species and suppresses inflammatory cascades, whereas siRNA‐VEGF achieves precise VEGF gene silencing, collectively interrupting the pathological cycle driving CNV progression. In a laser‐induced CNV mouse model, topical administration of Chi@Lu/si NPs twice daily exerted potent inhibitory effects on neovascularization, with therapeutic efficacy comparable to that of intravitreal bevacizumab, reducing CNV lesion thickness to 58.9% of pre‐treatment levels while maintaining excellent ocular biocompatibility.
- Open Access
Surface Hydrophobicity Dictates Environment‐dependent Colloidal Stability of Organic Phototheranostic Nanoparticles
Organic phototheranostic nanoparticles (OPNPs) have gained significant attention in bioimaging, sensing, and therapy owing to their tunable optical properties and multifunctional theranostic capabilities. Composed of amphiphilic polymeric carriers (APCs) and hydrophobic chromophores, their colloidal stability in aqueous environments is critical for preserving optical performance and ensuring in vivo efficacy. Herein, we systematically compare the colloidal stability of OPNPs in physiological saline versus the bloodstream, uncovering distinct environment‐dependent behaviors that are primarily governed by OPNP surface hydrophobicity, which is tunable via the intrinsic hydrophobicity of the APCs. Specifically, OPNPs prepared with higher hydrophobic carriers aggregate in saline but remain stable in the bloodstream, whereas those with less hydrophobic carriers show the opposite trend. Mechanistically, this environment‐dependent stability arises from differential interfacial interactions: surface hydrophobicity modulates ion‐induced poly(ethylene glycol) dehydration and aggregation in saline, while governing protein‐mediated stability regulation in serum. Overall, our findings establish surface hydrophobicity as a pivotal regulator of OPNP colloidal stability and provide a rational design principle for engineering OPNPs tailored to specific biomedical scenarios (e.g., in vitro detection vs. in vivo therapy).
Open AccessSurface Hydrophobicity Dictates Environment‐dependent Colloidal Stability of Organic Phototheranostic Nanoparticles
Organic phototheranostic nanoparticles (OPNPs) have gained significant attention in bioimaging, sensing, and therapy owing to their tunable optical properties and multifunctional theranostic capabilities. Composed of amphiphilic polymeric carriers (APCs) and hydrophobic chromophores, their colloidal stability in aqueous environments is critical for preserving optical performance and ensuring in vivo efficacy. Herein, we systematically compare the colloidal stability of OPNPs in physiological saline versus the bloodstream, uncovering distinct environment‐dependent behaviors that are primarily governed by OPNP surface hydrophobicity, which is tunable via the intrinsic hydrophobicity of the APCs. Specifically, OPNPs prepared with higher hydrophobic carriers aggregate in saline but remain stable in the bloodstream, whereas those with less hydrophobic carriers show the opposite trend. Mechanistically, this environment‐dependent stability arises from differential interfacial interactions: surface hydrophobicity modulates ion‐induced poly(ethylene glycol) dehydration and aggregation in saline, while governing protein‐mediated stability regulation in serum. Overall, our findings establish surface hydrophobicity as a pivotal regulator of OPNP colloidal stability and provide a rational design principle for engineering OPNPs tailored to specific biomedical scenarios (e.g., in vitro detection vs. in vivo therapy).
- 17 May 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (27)
Nanoscale Spatial Engineering of Ligands Using DNA Origami for Precise Modulation of Membrane Receptor Signaling
Dimerization or multimerization of surface membrane receptors is essential for transmitting extracellular recognition events across the plasma membrane, triggering intracellular signaling cascades, and regulating a wide range of cellular functions. Ligands typically act as inducers for these processes by binding to receptors, promoting their aggregation and subsequent dimerization or multimerization. The precise spatial arrangement of ligands is crucial for minimizing random collisions and non‐directed migration of receptors on the cell membrane, thereby enhancing signaling fidelity. DNA origami, a highly versatile self‐assembly technique, has emerged as a powerful tool for generating a wide variety of DNA nanostructures. Its exceptional programmability and spatial addressability enable fine‐tuned control over ligand spatial arrangement at the nanoscale, facilitating the precise modulation of surface membrane receptor signaling and enabling user‐defined biological investigations. In this review, we explore the methods used to engineer the spatial arrangement of ligands through DNA origami, highlighting its unique advantages in controlling ligand distance, valence, spatial configuration, and stoichiometry. We also present current applications of DNA origami for modulating membrane receptor signaling, while addressing the key challenges and future directions in achieving precise nanoscale spatial arrangements of ligands for biological and therapeutic purposes.
- 17 May 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (27)
Nanoscale Spatial Engineering of Ligands Using DNA Origami for Precise Modulation of Membrane Receptor Signaling
Dimerization or multimerization of surface membrane receptors is essential for transmitting extracellular recognition events across the plasma membrane, triggering intracellular signaling cascades, and regulating a wide range of cellular functions. Ligands typically act as inducers for these processes by binding to receptors, promoting their aggregation and subsequent dimerization or multimerization. The precise spatial arrangement of ligands is crucial for minimizing random collisions and non‐directed migration of receptors on the cell membrane, thereby enhancing signaling fidelity. DNA origami, a highly versatile self‐assembly technique, has emerged as a powerful tool for generating a wide variety of DNA nanostructures. Its exceptional programmability and spatial addressability enable fine‐tuned control over ligand spatial arrangement at the nanoscale, facilitating the precise modulation of surface membrane receptor signaling and enabling user‐defined biological investigations. In this review, we explore the methods used to engineer the spatial arrangement of ligands through DNA origami, highlighting its unique advantages in controlling ligand distance, valence, spatial configuration, and stoichiometry. We also present current applications of DNA origami for modulating membrane receptor signaling, while addressing the key challenges and future directions in achieving precise nanoscale spatial arrangements of ligands for biological and therapeutic purposes.
- 17 May 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (27) , e2621334
Nanoscale Spatial Engineering of Ligands Using DNA Origami for Precise Modulation of Membrane Receptor Signaling
Dimerization or multimerization of surface membrane receptors is essential for transmitting extracellular recognition events across the plasma membrane, triggering intracellular signaling cascades, and regulating a wide range of cellular functions. Ligands typically act as inducers for these processes by binding to receptors, promoting their aggregation and subsequent dimerization or multimerization. The precise spatial arrangement of ligands is crucial for minimizing random collisions and non‐directed migration of receptors on the cell membrane, thereby enhancing signaling fidelity. DNA origami, a highly versatile self‐assembly technique, has emerged as a powerful tool for generating a wide variety of DNA nanostructures. Its exceptional programmability and spatial addressability enable fine‐tuned control over ligand spatial arrangement at the nanoscale, facilitating the precise modulation of surface membrane receptor signaling and enabling user‐defined biological investigations. In this review, we explore the methods used to engineer the spatial arrangement of ligands through DNA origami, highlighting its unique advantages in controlling ligand distance, valence, spatial configuration, and stoichiometry. We also present current applications of DNA origami for modulating membrane receptor signaling, while addressing the key challenges and future directions in achieving precise nanoscale spatial arrangements of ligands for biological and therapeutic purposes.
- 17 May 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (27) , e2621334
Nanoscale Spatial Engineering of Ligands Using DNA Origami for Precise Modulation of Membrane Receptor Signaling
Dimerization or multimerization of surface membrane receptors is essential for transmitting extracellular recognition events across the plasma membrane, triggering intracellular signaling cascades, and regulating a wide range of cellular functions. Ligands typically act as inducers for these processes by binding to receptors, promoting their aggregation and subsequent dimerization or multimerization. The precise spatial arrangement of ligands is crucial for minimizing random collisions and non‐directed migration of receptors on the cell membrane, thereby enhancing signaling fidelity. DNA origami, a highly versatile self‐assembly technique, has emerged as a powerful tool for generating a wide variety of DNA nanostructures. Its exceptional programmability and spatial addressability enable fine‐tuned control over ligand spatial arrangement at the nanoscale, facilitating the precise modulation of surface membrane receptor signaling and enabling user‐defined biological investigations. In this review, we explore the methods used to engineer the spatial arrangement of ligands through DNA origami, highlighting its unique advantages in controlling ligand distance, valence, spatial configuration, and stoichiometry. We also present current applications of DNA origami for modulating membrane receptor signaling, while addressing the key challenges and future directions in achieving precise nanoscale spatial arrangements of ligands for biological and therapeutic purposes.
- Open Access
- 21 January 2026
- Published by Wiley in Small Structures
- Vol. 7 (1)
Smart Aggregation of DNA Nanostructures in Living Cells
Self‐aggregation processes are ubiquitous in living systems and play vital roles in maintaining normal physiological functions. Inspired by these natural phenomena, constructing artificial aggregates within cells is of great significance for understanding the complex mechanisms of life activities and precisely regulating cellular processes. Owing to its excellent programmability and stimulus responsiveness, DNA nanotechnology offers unprecedented opportunities for building intelligent nanodevices inside living cells, far more dynamically regulable than traditional materials. This review systematically summarizes recent strategies for achieving intelligent intracellular aggregation of DNA nanostructures in response to various stimuli, including protons, metal ions, enzymes, nucleic acids, and sequential stimuli. Furthermore, we discuss the specific applications of these DNA‐based smart aggregates, including in situ biosensing and cellular function regulation. Finally, we provide an outlook on key challenges and prospects in this emerging field.
- 21 January 2026
- Published by Wiley in Small Structures
- Vol. 7 (1)
Open AccessSmart Aggregation of DNA Nanostructures in Living Cells
Self‐aggregation processes are ubiquitous in living systems and play vital roles in maintaining normal physiological functions. Inspired by these natural phenomena, constructing artificial aggregates within cells is of great significance for understanding the complex mechanisms of life activities and precisely regulating cellular processes. Owing to its excellent programmability and stimulus responsiveness, DNA nanotechnology offers unprecedented opportunities for building intelligent nanodevices inside living cells, far more dynamically regulable than traditional materials. This review systematically summarizes recent strategies for achieving intelligent intracellular aggregation of DNA nanostructures in response to various stimuli, including protons, metal ions, enzymes, nucleic acids, and sequential stimuli. Furthermore, we discuss the specific applications of these DNA‐based smart aggregates, including in situ biosensing and cellular function regulation. Finally, we provide an outlook on key challenges and prospects in this emerging field.
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9, 1293
DNA Nanotechnology-Enabled Precise Regulation of Nanozymes and Their Applications
Nanozymes overcome key limitations of natural enzymes, including poor environmental tolerance, high production costs, and batch-to-batch variability, with their enhanced physicochemical stability and controllable catalytic performance, thus enabling applications in biocatalysis and disease theranostics. However, their practical applications remain limited by insufficient catalytic efficiency, inadequate target specificity, and restricted programmable dynamic adaptability. DNA nanotechnology offers a versatile and biocompatible framework for the precise regulation of nanozymes due to its sequence-defined programmability and precise molecular recognition capability. This approach improves catalytic performance while maintaining excellent biocompatibility and low immunogenicity. This review systematically summarizes the latest advances in DNA nanotechnology-mediated precise regulation of nanozymes, with particular emphasis on the mechanistic basis of 6 regulatory modes. We further examine the representative applications of these DNA–nanozyme hybrid systems in disease therapy, biomedical sensing, and environmental monitoring, and outline the key challenges and future directions toward clinical and industrial translation.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9, 1293
Open AccessDNA Nanotechnology-Enabled Precise Regulation of Nanozymes and Their Applications
Nanozymes overcome key limitations of natural enzymes, including poor environmental tolerance, high production costs, and batch-to-batch variability, with their enhanced physicochemical stability and controllable catalytic performance, thus enabling applications in biocatalysis and disease theranostics. However, their practical applications remain limited by insufficient catalytic efficiency, inadequate target specificity, and restricted programmable dynamic adaptability. DNA nanotechnology offers a versatile and biocompatible framework for the precise regulation of nanozymes due to its sequence-defined programmability and precise molecular recognition capability. This approach improves catalytic performance while maintaining excellent biocompatibility and low immunogenicity. This review systematically summarizes the latest advances in DNA nanotechnology-mediated precise regulation of nanozymes, with particular emphasis on the mechanistic basis of 6 regulatory modes. We further examine the representative applications of these DNA–nanozyme hybrid systems in disease therapy, biomedical sensing, and environmental monitoring, and outline the key challenges and future directions toward clinical and industrial translation.
- Open Access
- 11 March 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (11)
Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating the exploration of multimodal immunotherapy combinations. Traditional approaches combining conventional immune checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion and systemic toxicity. Hence, novel approaches are needed to address these challenges. Herein, we demonstrate that mRNA polymeric nanoparticles encoding anti-PD-1 antibodies in situ at the tumor site enhance the therapeutic efficacy of neoantigen-based mRNA vaccine for PDAC. This mRNA-based, in situ anti-PD-1 antibody production strategy also protects tumor-infiltrating T cells from PD-1 inhibition, potentially reducing the toxicities induced by systemic checkpoint inhibition. Our study may provide an innovative dual mRNA nanoparticle strategy for effective tumor neoantigen immunotherapy, as well as an mRNA cancer combination therapy strategy with other clinically approved drugs (e.g., β-elemene).
- 11 March 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (11)
Open AccessDual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating the exploration of multimodal immunotherapy combinations. Traditional approaches combining conventional immune checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion and systemic toxicity. Hence, novel approaches are needed to address these challenges. Herein, we demonstrate that mRNA polymeric nanoparticles encoding anti-PD-1 antibodies in situ at the tumor site enhance the therapeutic efficacy of neoantigen-based mRNA vaccine for PDAC. This mRNA-based, in situ anti-PD-1 antibody production strategy also protects tumor-infiltrating T cells from PD-1 inhibition, potentially reducing the toxicities induced by systemic checkpoint inhibition. Our study may provide an innovative dual mRNA nanoparticle strategy for effective tumor neoantigen immunotherapy, as well as an mRNA cancer combination therapy strategy with other clinically approved drugs (e.g., β-elemene).
- 3 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (51) , 35252-35263
Elemene Hydrogel Modulates the Tumor Immune Microenvironment for Enhanced Treatment of Postoperative Cancer Recurrence and Metastases
As a representative active ingredient of traditional Chinese medicine (TCM) and a clinically approved anticancer drug, elemene (ELE) exhibits exciting potential in the antitumor field; however, appropriate drug formulations still need to be explored for specific diseases such as postoperative cancer recurrence and metastasis. Herein, we report an ELE hydrogel with controlled drug release kinetics that can allow ELE to maintain effective concentrations at local lesion sites for extended periods to enhance the bioavailability of ELE. Concretely, dopamine-conjugated hyaluronic acid is synthesized and utilized to prepare ELE nanodrug-embedded hydrogels. In a model of postoperative breast cancer recurrence and metastasis, the ELE hydrogel demonstrates a 96% inhibition rate of recurrence; in contrast, the free ELE nanodrug shows only a 65.5% inhibition rate of recurrence. Importantly, the ELE hydrogel markedly stimulates a potent antitumor immune response in the microenvironment of cancer lesions, increasing antitumor immune cells such as CD8+ T cells, CD4+ T cells, and M1-type macrophages, as well as elevating antitumor cytokines including TNF-α, IFN-γ, and IL-6. Overall, this study not only advances the field of TCM but also highlights the transformative impact of controlled-release hydrogels in improving antitumor therapy.
- 3 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (51) , 35252-35263
Elemene Hydrogel Modulates the Tumor Immune Microenvironment for Enhanced Treatment of Postoperative Cancer Recurrence and Metastases
As a representative active ingredient of traditional Chinese medicine (TCM) and a clinically approved anticancer drug, elemene (ELE) exhibits exciting potential in the antitumor field; however, appropriate drug formulations still need to be explored for specific diseases such as postoperative cancer recurrence and metastasis. Herein, we report an ELE hydrogel with controlled drug release kinetics that can allow ELE to maintain effective concentrations at local lesion sites for extended periods to enhance the bioavailability of ELE. Concretely, dopamine-conjugated hyaluronic acid is synthesized and utilized to prepare ELE nanodrug-embedded hydrogels. In a model of postoperative breast cancer recurrence and metastasis, the ELE hydrogel demonstrates a 96% inhibition rate of recurrence; in contrast, the free ELE nanodrug shows only a 65.5% inhibition rate of recurrence. Importantly, the ELE hydrogel markedly stimulates a potent antitumor immune response in the microenvironment of cancer lesions, increasing antitumor immune cells such as CD8+ T cells, CD4+ T cells, and M1-type macrophages, as well as elevating antitumor cytokines including TNF-α, IFN-γ, and IL-6. Overall, this study not only advances the field of TCM but also highlights the transformative impact of controlled-release hydrogels in improving antitumor therapy.
- Open Access
- 26 February 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (18) , 8791-8806
Unleashing the potential: integrating nano-delivery systems with traditional Chinese medicine
This minireview summarizes the utility of integrating nano-delivery systems with TCM, emphasizing their capacity to enhance treatment efficacy, modernize TCM, and expand global accessibility.
- 26 February 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (18) , 8791-8806
Open AccessUnleashing the potential: integrating nano-delivery systems with traditional Chinese medicine
This minireview summarizes the utility of integrating nano-delivery systems with TCM, emphasizing their capacity to enhance treatment efficacy, modernize TCM, and expand global accessibility.
- Open Access
- 25 October 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (44)
Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection
Messenger RNA (mRNA)–based therapeutics are transforming the landscapes of medicine, yet targeted delivery of mRNA to specific cell types while minimizing off-target accumulation remains challenging for mRNA-mediated therapy. In this study, we report an innovative design of a cationic lipid- and hyaluronic acid–based, dual-targeted mRNA nanoformulation that can display the desirable stability and efficiently transfect the targeted proteins into lung tissues. More importantly, the optimized dual-targeted mRNA nanoparticles (NPs) can not only accumulate primarily in lung tumor cells and inflammatory macrophages after inhalation delivery but also efficiently express any desirable proteins (e.g., p53 tumor suppressor for therapy, as well as luciferase and green fluorescence protein for imaging as examples in this study) and achieve efficacious lung tissue transfection in vivo. Overall, our findings provide proof-of-principle evidence for the design and use of dual-targeted mRNA NPs in homing to specific cell types to up-regulate target proteins in lung tissues, which may hold great potential for the future development of mRNA-based inhaled medicines or vaccines in treating various lung-related diseases.
- 25 October 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (44)
Open AccessInhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection
Messenger RNA (mRNA)–based therapeutics are transforming the landscapes of medicine, yet targeted delivery of mRNA to specific cell types while minimizing off-target accumulation remains challenging for mRNA-mediated therapy. In this study, we report an innovative design of a cationic lipid- and hyaluronic acid–based, dual-targeted mRNA nanoformulation that can display the desirable stability and efficiently transfect the targeted proteins into lung tissues. More importantly, the optimized dual-targeted mRNA nanoparticles (NPs) can not only accumulate primarily in lung tumor cells and inflammatory macrophages after inhalation delivery but also efficiently express any desirable proteins (e.g., p53 tumor suppressor for therapy, as well as luciferase and green fluorescence protein for imaging as examples in this study) and achieve efficacious lung tissue transfection in vivo. Overall, our findings provide proof-of-principle evidence for the design and use of dual-targeted mRNA NPs in homing to specific cell types to up-regulate target proteins in lung tissues, which may hold great potential for the future development of mRNA-based inhaled medicines or vaccines in treating various lung-related diseases.